Research programme: antimicrobial therapeutics - Novoclem Therapeutics/University of North Carolina

Drug Profile

Research programme: antimicrobial therapeutics - Novoclem Therapeutics/University of North Carolina

Alternative Names: BIOC 51

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novoclem Therapeutics; University of North Carolina at Chapel Hill
  • Developer Novoclem Therapeutics
  • Class Antibacterials
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 07 Nov 2017 BIOC-51 receives Qualified Infectious Disease Product status for Bacterial infections in USA
  • 11 Apr 2017 Preclinical development in Bacterial infections in USA
  • 11 Apr 2017 Novoclem Therapeutics announces intention to submit IND to US FDA in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top